NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ:REGN) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=132369&wire=3
REGN investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company’s primary products, Eylea customers more to …